RVNC Deadline: RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding purchasers of Revance Therapeutics, Inc. securities about the upcoming lead plaintiff deadline for a class action lawsuit, indicating potential compensation for affected investors [1][2]. Group 1: Class Action Details - The class action pertains to securities purchased between February 29, 2024, and December 6, 2024, with a lead plaintiff deadline set for March 4, 2025 [1]. - Investors can join the class action without incurring out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3]. Group 3: Case Allegations - The lawsuit alleges that Revance made false and misleading statements and failed to disclose material breaches of agreements, which increased litigation risks and potential harm [4]. - Specific claims include breaches of the Distribution Agreement with Teoxane SA and issues related to a contract with an unreliable partner, leading to misleading public statements [4].